Delving into the Latest Updates on Huayi Pharmaceutical Technology (Anhui) Co., Ltd. with Synapse

Overview

Tags

Cardiovascular Diseases

Small molecule drug

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

No Data

Disease Domain	Count

Hemic and Lymphatic Diseases	1
Endocrinology and Metabolic Disease	1

Top 5 Drug Type	Count

Small molecule drug	1

研究空腹和餐后状态下单次口服受试制剂（氢化可的松片，规格10mg，大玮（安徽）药业有限公司持证）和参比制剂（氢化可的松片，规格10mg，PHARMACIA AND UPJOHN CO持证）在健康试验参与者体内的药代动力学特征，比较受试制剂与参比制剂的生物等效性，并研究药物在健康试验参与者体内的安全性。

[Translation]

This study investigated the pharmacokinetic characteristics of a single oral dose of the test formulation (hydrocortisone tablets, 10 mg, certified by Dawei (Anhui) Pharmaceutical Co., Ltd.) and the reference formulation (hydrocortisone tablets, 10 mg, certified by PHARMACIA AND UPJOHN CO.) in healthy trial participants under fasting and postprandial conditions, compared the bioequivalence of the test and reference formulations, and studied the safety of the drugs in healthy trial participants.

Start Date06 May 2026

Sponsor / Collaborator

Dawei (Anhui) Pharmaceutical Co., Ltd.

CTR20260934

/ CompletedNot Applicable

乙酰半胱氨酸片在健康受试者中餐后条件下开放、随机、单次给药、两制剂、两序列、两周期交叉设计生物等效性试验

[Translation] An open-label, randomized, single-dose, two-formulation, two-sequence, two-period crossover bioequivalence study of acetylcysteine tablets in healthy subjects under postprandial conditions.

研究餐后状态下单次口服受试制剂（乙酰半胱氨酸片，规格0.6g，华益药业科技(安徽)有限公司生产）与参比制剂（乙酰半胱氨酸片，规格600mg，商品名：Fluimucil，Zambon Nederland B.V.生产）在健康受试者体内的药代动力学特征，比较受试制剂与参比制剂的生物等效性，并研究药物在健康受试者体内的安全性。

[Translation]

This study investigated the pharmacokinetic characteristics of a single oral dose of the test formulation (acetylcysteine tablets, 0.6g, manufactured by Huayi Pharmaceutical Technology (Anhui) Co., Ltd.) and the reference formulation (acetylcysteine tablets, 600mg, trade name: Fluimucil, manufactured by Zambon Nederland B.V.) in healthy subjects after a meal, compared the bioequivalence of the test and reference formulations, and studied the safety of the drugs in healthy subjects.

Start Date25 Feb 2026

Sponsor / Collaborator

Huayi Pharmaceutical Technology (Anhui) Co., Ltd.

CTR20254426

/ CompletedNot Applicable

达格列净片在健康参与者中空腹与餐后条件下开放、随机、单次给药、两制剂、两序列、两周期交叉设计生物等效性试验

[Translation] An open-label, randomized, single-dose, two-formulation, two-sequence, two-period crossover bioequivalence study of dapagliflozin tablets in healthy participants under fasting and postprandial conditions.

研究空腹与餐后状态下单次口服受试制剂（达格列净片，规格10mg（以C21H25ClO6计），华益药业科技（安徽）有限公司持证）与参比制剂（达格列净片，规格10mg（以C21H25ClO6计），商品名安达唐/FORXIGA，AstraZeneca AB持证）在健康参与者体内的药代动力学特征，比较受试制剂与参比制剂的生物等效性，并研究药物在健康参与者体内的安全性。

[Translation]

This study investigated the pharmacokinetic characteristics of a single oral dose of the test formulation (dapagliflozin tablets, 10 mg (C21H25ClO6), certified by Huayi Pharmaceutical Technology (Anhui) Co., Ltd.) and the reference formulation (dapagliflozin tablets, 10 mg (C21H25ClO6), trade name FORXIGA, certified by AstraZeneca AB) in healthy participants under fasting and postprandial conditions, compared the bioequivalence of the test and reference formulations, and studied the safety of the drugs in healthy participants.

Start Date28 Nov 2025

Sponsor / Collaborator

Huayi Pharmaceutical Technology (Anhui) Co., Ltd.

100 Clinical Results associated with Huayi Pharmaceutical Technology (Anhui) Co., Ltd.

Login to view more data

0 Patents (Medical) associated with Huayi Pharmaceutical Technology (Anhui) Co., Ltd.

Login to view more data

100 Deals associated with Huayi Pharmaceutical Technology (Anhui) Co., Ltd.

Login to view more data

100 Translational Medicine associated with Huayi Pharmaceutical Technology (Anhui) Co., Ltd.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 08 Nov 2026

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Phase 1

1

Login to view more data